Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wensink, G. Emerens, Elias, Sjoerd G., Mullenders, Jasper, Koopman, Miriam, Boj, Sylvia F., Kranenburg, Onno W., Roodhart, Jeanine M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042051/
https://www.ncbi.nlm.nih.gov/pubmed/33846504
http://dx.doi.org/10.1038/s41698-021-00168-1
_version_ 1783678052197203968
author Wensink, G. Emerens
Elias, Sjoerd G.
Mullenders, Jasper
Koopman, Miriam
Boj, Sylvia F.
Kranenburg, Onno W.
Roodhart, Jeanine M. L.
author_facet Wensink, G. Emerens
Elias, Sjoerd G.
Mullenders, Jasper
Koopman, Miriam
Boj, Sylvia F.
Kranenburg, Onno W.
Roodhart, Jeanine M. L.
author_sort Wensink, G. Emerens
collection PubMed
description Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.
format Online
Article
Text
id pubmed-8042051
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80420512021-04-28 Patient-derived organoids as a predictive biomarker for treatment response in cancer patients Wensink, G. Emerens Elias, Sjoerd G. Mullenders, Jasper Koopman, Miriam Boj, Sylvia F. Kranenburg, Onno W. Roodhart, Jeanine M. L. NPJ Precis Oncol Review Article Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients. Nature Publishing Group UK 2021-04-12 /pmc/articles/PMC8042051/ /pubmed/33846504 http://dx.doi.org/10.1038/s41698-021-00168-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Wensink, G. Emerens
Elias, Sjoerd G.
Mullenders, Jasper
Koopman, Miriam
Boj, Sylvia F.
Kranenburg, Onno W.
Roodhart, Jeanine M. L.
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_full Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_fullStr Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_full_unstemmed Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_short Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_sort patient-derived organoids as a predictive biomarker for treatment response in cancer patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042051/
https://www.ncbi.nlm.nih.gov/pubmed/33846504
http://dx.doi.org/10.1038/s41698-021-00168-1
work_keys_str_mv AT wensinkgemerens patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
AT eliassjoerdg patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
AT mullendersjasper patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
AT koopmanmiriam patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
AT bojsylviaf patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
AT kranenburgonnow patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
AT roodhartjeanineml patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients

Ejemplares similares